Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma
brief summary
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of systemic therapy and are naïve (not previously treated with) standard of care tyrosine kinase inhibitors targeting vascular endothelial growth factor signaling.
detailed description
This Phase I/II investigator-sponsored trial will evaluate the combination of zanzalintinib (XL092) and tegavivint in participants with advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations (CTNNB1, AXIN1, CREBBP, APC) who have progressed after at least one prior line of systemic therapy and are VEGFR-TKI naïve. The study employs a two-part design beginning with a Phase I dose escalation using a Bayesian Optimal Interval (BOIN) design with cohorts of 3-6 participants per dose level to determine the safety and tolerability of the combination. The dose escalation will evaluate tegavivint in combination with fixed-dose zanzalintinib. A maximum of 12 evaluable participants will be enrolled in the dose escalation phase to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of tegavivint when combined with zanzalintinib.
official title
A Phase 1/2 Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma